Search
TG Therapeutics Inc
TGTXAdd to Watchlist
55.900USD
+0.180+0.32%
Market hours （ET）Quotes delayed by 15 min
8.56BMarket Cap
17.46P/E TTM
More Details of TG Therapeutics Inc Company
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
TG Therapeutics Inc Info
Ticker SymbolTGTX
Company nameTG Therapeutics Inc
IPO dateDec 14, 1995
CEOWeiss (Michael S)
Number of employees338
Security typeOrdinary Share
Fiscal year-endDec 14
Address3020 Carrington Mill Blvd., Suite 475
CityMORRISVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27560-5435
Phone18775758489
Websitehttps://www.tgtherapeutics.com/
Ticker SymbolTGTX
IPO dateDec 14, 1995
CEOWeiss (Michael S)
Company Executives of TG Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
--
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
--
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
--
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
--
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
--
Dr. Sagar Lonial
Dr. Sagar Lonial
Independent Director
Independent Director
94.06K
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
--
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
--
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
--
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
--
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
--
FAQs
Who are the top five shareholders of TG Therapeutics Inc?
The top five shareholders of TG Therapeutics Inc are: Mr. Michael S. Weiss, J.D.
How many institutions hold shares of TG Therapeutics Inc (TGTX)?
As of 2026Q1, 760 institutions hold shares of TG Therapeutics Inc, with a combined market value of approximately 122.50M, accounting for 80.02% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 4398281.00.
What is the biggest source of revenue for TG Therapeutics Inc?
In 2026Q1, the Total product revenue, net business generated the highest revenue for TG Therapeutics Inc, amounting to 606.93M and accounting for 98.48% of total revenue.
